Single-Chain Chimeric Polypeptides Using Soluble Tissue Factor Scaffolds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanism of 'decryption' of cell-surface tissue factor for coagulation is unclear, and existing technologies do not effectively utilize soluble tissue factor as a scaffold for chimeric polypeptides to stimulate immune cells or treat diseases.
Innovation Solution
Development of single-chain chimeric polypeptides comprising a first and second target-binding domain, with a soluble tissue factor domain as a scaffold, which can be used to stimulate immune cells and treat various diseases by contacting them with immune cells or administering to subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If soluble tissue factor is used as a scaffold for chimeric polypeptides, then the ability to stimulate immune cells and treat diseases is improved, but the mechanism of decryption for coagulation remains unclear and utilization is ineffective
Solution Approach 1:
The patent uses soluble tissue factor as an intermediary scaffold to bridge target-binding domains and immune cell stimulation. The soluble TF domain acts as a mediator that can be decrypted through controlled mechanisms (such as proteolytic cleavage or conformational changes) to activate coagulation pathways while maintaining immune stimulation functionality. This resolves the contradiction by providing a reliable, controllable mechanism for decryption while preserving the versatile therapeutic applications.
2Adaptability or versatility
If chimeric polypeptides are designed with multiple target-binding domains and soluble tissue factor scaffold, then therapeutic benefits are enhanced, but structural complexity increases
Solution Approach 1:
The patent merges multiple functional domains (target-binding domains, soluble tissue factor scaffold, and immune stimulation elements) into a single chimeric polypeptide structure. This consolidation achieves multiple therapeutic benefits simultaneously while managing structural complexity through modular design principles, where each domain performs a specific function within the integrated molecule.
Solution Approach 2:
The chimeric polypeptide structure is designed with universal applicability through the soluble tissue factor scaffold that can interact with multiple immune cell types and pathways. The multi-functional design allows a single molecular architecture to provide diverse therapeutic benefits across different disease contexts, enhancing versatility without proportionally increasing complexity.
3Productivity
If soluble tissue factor is utilized effectively, then coagulation initiation and immune stimulation are improved, but the decryption mechanism remains unclear
Solution Approach 1:
The patent implements preliminary action by pre-configuring the chimeric polypeptide with soluble tissue factor domains that are ready for controlled activation. The structure is designed in advance with specific decryption mechanisms (such as protease-sensitive linkers or conformational switches) that can be triggered under defined conditions. This approach improves productivity by ensuring rapid and efficient coagulation initiation and immune stimulation while reducing information loss through predetermined, characterizable decryption pathways.
Data Source
AI summary
Provided herein are single-chain chimeric polypeptides that include: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a second target-binding domain. Also provided here are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.